Cero Therapeutics Secures $750K Convertible Note with Highly Dilutive Terms

summarizeSummary

Cero Therapeutics Holdings, Inc. has issued and sold a convertible promissory note for $750,000, with a principal face value of $937,500, featuring highly dilutive conversion terms tied to market price.

check_boxKey Events · Financing and Capital Events · CERO

• Convertible Note Issued

  Cero Therapeutics issued and sold a convertible promissory note for a purchase price of $750,000, with a principal face value of $937,500, to Keystone Capital Partners, LLC.

• Highly Dilutive Terms

  The note is convertible into common stock at the lesser of $0.05 or 80% of the average of the five lowest intraday trading prices over 20 days, indicating significant potential dilution for existing shareholders.

• Substantial Capital Raise

  The $750,000 financing represents a substantial capital raise relative to the company's current valuation, highlighting a critical need for funding.

• Trading Near 52-Week Lows

  This dilutive financing occurs while the company's stock is trading near its 52-week low, exacerbating the impact on shareholder value.

auto_awesomeAnalysis · CERO · Life Sciences

This filing reports the actual issuance and sale of a significant convertible promissory note, representing over 100% of the company's current market capitalization. The note's conversion terms, which allow conversion at 80% of the lowest average trading prices, are highly unfavorable to existing shareholders and indicate a "death spiral" financing structure. This capital raise, occurring while the stock trades near its 52-week low, suggests the company is in a distressed financial position and is securing funding at a substantial cost to equity holders. The requirement to register shares for resale further adds to potential future dilution.